Interim report January – June 2017
CEO’s comments EQL Pharma has had a weak quarter, which is in line with the outlook presented in the year-end report. The temporary recall of our top seller Hydroxyzin EQL Pharma has, as previously communicated, affected our sales and our results. The quarter has been characterized by a high level of activity in business development. An agreement for in-licensing have been signed and final stage negotiations are ongoing for a handful of products in new development and in-licensing. The pharmaceutical product Kaliumklorid EQL Pharma (potassium chloride tablets) has been approved by